Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

PRS Efficacy Criteria for Good-Evidence (Tier II) Medication Adherence (MA) Behavioral Interventions

Intervention Description

  • Clear description of key aspects of the intervention

Quality of Study Design

  • At least a quasi-prospective study design
  • Appropriate comparison arm
  • At least a non-concurrent comparison arm that was implemented within 12 months of the start of the intervention and was similar with respect to population characteristics and setting
  • At least non-random allocation with minimal or moderate selection bias unrelated to the intervention or adherence behavior.

Quality of Study Implementation

  • At least a 1-month post-intervention follow-up assessment for each study arm (with recall referring to post-intervention period only) for interventions that are clearly discrete or at least a 3-months post-initiation follow-up assessment for each study arm for all other types of interventions
  • At least a 60% retention rate (or medical chart recovery) at a single required assessment time point for each study arm

Quality of Study analysis

  • Analysis contrasting intervention arm and an appropriate comparison arm
  • Intent-to-treat analysis:
    • Analysis of participants in study arms as originally allocated
    • Analysis of participants regardless of the level of intervention exposure
  • Comparability of measures:
    • Measures must be identical, including recall, for any repeated measures or change score analyses
    • Baseline measures do not have to be identical, but must be of the same construct as outcome measures, if being used as a covariate in analyses (i.e., adjusted for BL)
  • Analysis based on a 2-sided test and an α =.05 (or more stringent)
  • Analytic sample of at least 40 participants per study arm
  • Non-randomized controlled trials (Non-RCTs) must either demonstrate baseline equivalence or control for baseline differences in outcome variables. Non-RCTs with moderate bias must also demonstrate baseline equivalence or control for baseline differences in demographics and other critical variables.

Top of Page

Strength of Evidence–Significant positive intervention effects

  • Positive and statistically significant (p < .05) intervention effect for at least 1 relevant behavioral outcome measure or 1 relevant biologic outcome measure
    • A positive intervention effect is defined as a statistically significant greater improvement in, or better level of, medication adherence behavioral or biologic outcome in the intervention arm relative to the comparison arm.
    • A relevant behavioral outcome measure may include electronic data monitoring (e.g., MEMs caps), pill count, pharmacy refill, or self-reported adherence. A relevant biologic outcome measure may include a lab test or medical chart recovery of HIV viral load levels.
  • Effect at the follow-up and based on the analyses that meet study design, implementation and analysis criteria

Strength of Evidence–Negative intervention effects

  • No negative and statistically significant (p < .05) intervention effect for any HIV-related behavioral or biologic outcome
    • A negative intervention effect is defined as a statistically significant greater improvement in, or better level of, HIV-related behavioral or biologic outcomes in the comparison arm relative to the intervention arm.
  • No other statistically significant harmful intervention effect
  • For an intervention with a replication evaluation, no significant negative intervention effects in the replication study

Additional Limitations to Evaluate:

  • The totality of the limitations (as described below) cannot introduce considerable bias that substantially reduces the confidence placed on the findings.
  • Examples of limitations to check include:
    • Intervention and comparison arms did not receive similar medication regimens
    • Findings based on too many post-hoc analyses
    • Inconsistent evidence between effects
    • Inconsistent evidence across intervention comparisons within the study
    • Effects only found within a potentially biased subgroup analysis
    • Substantial (>40%) overall missing data (due to attrition and non-attrition such as missing responses)
    • Substantial differential attrition in rates (>10%) or participant characteristics across study arms
    • Differences in characteristics between those lost-to-follow up and those retained in the study
    • Any other notable bias threatening internal or external validity

All criteria must be satisfied for an intervention to be considered as a good-evidence MA intervention

Back to HIV Medication Adherence Efficacy Criteria

Top of Page



Find an HIV testing site near you.

For additional HIV services, select the "More" tab.

Search location, such as: "Atlanta, GA", or "30033".

For more information on this widget, please visit

Please contact with any comments, suggestions, or concerns.


Syndicate This Content Podcast button Tell us what you think button CDC-INFO The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO